WO2007100607A3 - Immunogenic peptides and methods of use - Google Patents

Immunogenic peptides and methods of use Download PDF

Info

Publication number
WO2007100607A3
WO2007100607A3 PCT/US2007/004603 US2007004603W WO2007100607A3 WO 2007100607 A3 WO2007100607 A3 WO 2007100607A3 US 2007004603 W US2007004603 W US 2007004603W WO 2007100607 A3 WO2007100607 A3 WO 2007100607A3
Authority
WO
WIPO (PCT)
Prior art keywords
page4
polypeptides
vectors
methods
polynucleotides
Prior art date
Application number
PCT/US2007/004603
Other languages
French (fr)
Other versions
WO2007100607A2 (en
Inventor
Jeffrey Schlom
Kwong-Yok Tsang
Ira H Pastan
Original Assignee
Us Gov Health & Human Serv
Jeffrey Schlom
Kwong-Yok Tsang
Ira H Pastan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38459544&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2007100607(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Us Gov Health & Human Serv, Jeffrey Schlom, Kwong-Yok Tsang, Ira H Pastan filed Critical Us Gov Health & Human Serv
Priority to DE602007009941T priority Critical patent/DE602007009941D1/en
Priority to EP07751371A priority patent/EP1989224B1/en
Priority to US12/280,534 priority patent/US7910692B2/en
Priority to AU2007221255A priority patent/AU2007221255B2/en
Priority to CA2642994A priority patent/CA2642994C/en
Priority to AT07751371T priority patent/ATE485305T1/en
Priority to DK07751371.1T priority patent/DK1989224T3/en
Publication of WO2007100607A2 publication Critical patent/WO2007100607A2/en
Publication of WO2007100607A3 publication Critical patent/WO2007100607A3/en
Priority to US13/025,094 priority patent/US9175057B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464493—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/023—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a poxvirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70517—CD8
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Developmental Biology & Embryology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The PAGE4 gene is expressed in reproductive tissues, and is expressed in reproductive cancers, such as prostate cancer, uterine cancer, and testicular cancer. Immunogenic PAGE4 polypeptides are disclosed herein, as are nucleic acids encoding the immunogenic PAGE4 polypeptides, vectors including these polynucleotides, and host cells transformed with these vectors. These polypeptides, polynucleotides, vectors, and host cells can be used to induce an immune response to PAGE4. Diagnostic methods to detect PAGE4 are also described.
PCT/US2007/004603 2006-02-24 2007-02-21 Immunogenic peptides and methods of use WO2007100607A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
DE602007009941T DE602007009941D1 (en) 2006-02-24 2007-02-21 IMMUNOGENEOUS PEPTIDES AND USE METHOD THEREFOR
EP07751371A EP1989224B1 (en) 2006-02-24 2007-02-21 Immunogenic peptides and methods of use
US12/280,534 US7910692B2 (en) 2006-02-24 2007-02-21 Immunogenic peptides and methods of use
AU2007221255A AU2007221255B2 (en) 2006-02-24 2007-02-21 Immunogenic peptides and methods of use
CA2642994A CA2642994C (en) 2006-02-24 2007-02-21 Immunogenic page-4 peptides and methods of use
AT07751371T ATE485305T1 (en) 2006-02-24 2007-02-21 IMMUNOGENIC PEPTIDES AND METHODS OF USE THEREOF
DK07751371.1T DK1989224T3 (en) 2006-02-24 2007-02-21 Immunogenic peptides and methods of use
US13/025,094 US9175057B2 (en) 2006-02-24 2011-02-10 Immunogenic peptides and methods of use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77650606P 2006-02-24 2006-02-24
US60/776,506 2006-02-24

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US28053408A Continuation 2006-02-24 2008-08-22
US13/025,094 Continuation US9175057B2 (en) 2006-02-24 2011-02-10 Immunogenic peptides and methods of use

Publications (2)

Publication Number Publication Date
WO2007100607A2 WO2007100607A2 (en) 2007-09-07
WO2007100607A3 true WO2007100607A3 (en) 2008-03-06

Family

ID=38459544

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/004603 WO2007100607A2 (en) 2006-02-24 2007-02-21 Immunogenic peptides and methods of use

Country Status (9)

Country Link
US (2) US7910692B2 (en)
EP (1) EP1989224B1 (en)
AT (1) ATE485305T1 (en)
AU (1) AU2007221255B2 (en)
CA (1) CA2642994C (en)
DE (1) DE602007009941D1 (en)
DK (1) DK1989224T3 (en)
ES (1) ES2356574T3 (en)
WO (1) WO2007100607A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60117164T2 (en) * 2000-11-07 2006-08-03 Immuno Vaccine Technologies Inc., Halifax VACCINES WITH INCREASED IMMUNE RESPONSE AND METHOD FOR THE PRODUCTION THEREOF
CA2642994C (en) * 2006-02-24 2015-09-01 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Immunogenic page-4 peptides and methods of use
JP5731198B2 (en) 2007-09-27 2015-06-10 イムノバクシーン・テクノロジーズ・インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． Use of liposomes in carriers containing a continuous hydrophobic phase for delivery of polynucleotides in vivo
US20100209452A1 (en) * 2007-10-03 2010-08-19 Immunovaccine Technologies, Inc Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
JP5715051B2 (en) 2008-06-05 2015-05-07 イムノバクシーン・テクノロジーズ・インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． Composition comprising carrier comprising liposome, antigen, polynucleotide and continuous phase of hydrophobic substance
US10105435B2 (en) 2011-10-06 2018-10-23 Immunovaccine Technologies Inc. Liposome compositions comprising an adjuvant that activates or increases the activity of TLR2 and uses thereof
CA2865553A1 (en) 2012-03-15 2013-09-19 Macrocure, Ltd. Activated immunostimulatory cell composition and uses thereof
US9725494B2 (en) * 2013-05-17 2017-08-08 United States Of America, As Represented By The Secretary, Department Of Health And Human Services Soluble CD27 (sCD27) and the use thereof
AU2016206682B2 (en) 2015-01-14 2021-11-11 The Brigham And Women's Hospital, Inc. Treatment of cancer with anti-LAP monoclonal antibodies
EP3261669B1 (en) 2015-02-25 2022-08-03 Memorial Sloan Kettering Cancer Center Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
US11254914B2 (en) 2015-03-12 2022-02-22 Health Research, Inc. Enrichment of CD16+ monocytes to improve dendritic cell vaccine quality
EP3283529B1 (en) 2015-04-17 2023-06-07 The General Hospital Corporation Agents, systems and methods for treating cancer
US10548930B2 (en) 2015-04-17 2020-02-04 Memorial Sloan Kettering Cancer Center Use of MVA or MVAΔE3L as immunotherapeutic agents against solid tumors
ES2785503T3 (en) 2015-11-09 2020-10-07 Immune Design Corp Compositions comprising IL-12 expressing lentiviral vectors and methods of using the same
SG11201807051VA (en) 2016-02-25 2018-09-27 Memorial Sloan Kettering Cancer Center Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy
CN109152827B (en) 2016-02-25 2023-07-21 纪念斯隆凯特琳癌症中心 Recombinant MVA or MVA delta E3L expressing human FLT3L and use thereof as immunotherapeutic agent against solid tumors
MA49122A (en) * 2017-04-10 2021-03-24 Immatics Biotechnologies Gmbh PEPTIDES AND COMBINATIONS OF PEPTIDES INTENDED FOR USE IN ANTI-CANCER IMMUNOTHERAPY
US11242509B2 (en) 2017-05-12 2022-02-08 Memorial Sloan Kettering Cancer Center Vaccinia virus mutants useful for cancer immunotherapy
CN110305217B (en) 2018-03-27 2022-03-29 广州爱思迈生物医药科技有限公司 Bispecific antibodies and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000012706A1 (en) * 1998-09-01 2000-03-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Page-4, an x-linked gage-like gene expressed in normal and neoplastic prostate, testis and uterus, and uses therefor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
DE69519521T2 (en) 1994-10-03 2001-06-28 Us Gov Nat Inst Health COMPOSITION CONTAINING AN ANTIQUE-EXPRESSING RECOMBINANT VIRUS AND AN IMMUNE-STIMULATING MOLECULE-EXPRESSING RECOMBINANT VIRUS
US6045802A (en) 1994-10-03 2000-04-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule
US6756038B1 (en) 1997-10-10 2004-06-29 The United States Of America As Represented By The Department Of Health And Human Services Agonist and antagonist peptides of carcinoembryonic antigen (CEA)
US6969609B1 (en) 1998-12-09 2005-11-29 The United States Of America As Represented By The Department Of Health And Human Serivces Recombinant vector expressing multiple costimulatory molecules and uses thereof
EP1461073B1 (en) 2001-11-30 2010-01-06 The Government of the United States of America, as represented by the Secretary Department of Health and Human Services Peptide agonists of prostate-specific antigen, and uses therefor
CA2642994C (en) * 2006-02-24 2015-09-01 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Immunogenic page-4 peptides and methods of use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000012706A1 (en) * 1998-09-01 2000-03-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Page-4, an x-linked gage-like gene expressed in normal and neoplastic prostate, testis and uterus, and uses therefor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YOKOKAWA JUNKO ET AL: "Identification of cytotoxic T-lymphocyte epitope(s) and its agonist epitope(s) of a novel target for vaccine therapy", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 47, April 2006 (2006-04-01), & 97TH ANNUAL MEETING OF THE AMERICAN-ASSOCIATION-FOR-CANCER-RESEARCH (AACR); WASHINGTON, DC, USA; APRIL 01 -05, 2006, pages 530 - 531, XP001536837, ISSN: 0197-016X *

Also Published As

Publication number Publication date
ES2356574T3 (en) 2011-04-11
US20090035266A1 (en) 2009-02-05
US9175057B2 (en) 2015-11-03
WO2007100607A2 (en) 2007-09-07
US20110165117A1 (en) 2011-07-07
US7910692B2 (en) 2011-03-22
CA2642994A1 (en) 2007-09-07
AU2007221255B2 (en) 2012-03-08
DK1989224T3 (en) 2011-02-14
EP1989224A2 (en) 2008-11-12
ATE485305T1 (en) 2010-11-15
DE602007009941D1 (en) 2010-12-02
CA2642994C (en) 2015-09-01
AU2007221255A1 (en) 2007-09-07
EP1989224B1 (en) 2010-10-20

Similar Documents

Publication Publication Date Title
WO2007100607A3 (en) Immunogenic peptides and methods of use
IL250946B (en) Nanobodies tm against tumor necrosis factor-alpha
WO2006113277A3 (en) Multivalent soluble tyrokinase receptor that bind angiogenic factor
WO2005121331A8 (en) Truncated galnact2 polypeptides and nucleic acids
EP2977382A3 (en) Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same
WO2008106551A8 (en) Brachyury polypeptides and methods for use
WO2007042289A3 (en) Nanobodies™ and polypeptides against egfr and igf-ir
WO2006056480A3 (en) Means and methods for detecting methylated dna
WO2009085935A3 (en) Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same
WO2009085864A3 (en) Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same
EP4050027A3 (en) Cx3cr1-binding polypeptides
DE602005019238D1 (en) OTEINEN
WO2005092918A3 (en) Targeting polypeptide
WO2009093242A3 (en) Cell populations for polypeptide analysis and uses of same
EP1789452A4 (en) Relaxin-chimeric polypeptides and their preparation and use
WO2007013479A3 (en) Genes and polypeptides relating to prostate cancers
WO2003090778A3 (en) Dna vaccine combined with an inducer of tumor cell apoptosis
PL1716169T3 (en) Ornithobacterium rhinotracheale subunit vaccines
Symchych et al. Experimental approaches to elaboration on the diagnostic test based on embryo proteins
WO2009020824A8 (en) Polynucleotides encoding stop codons in multiple reading frames and methods of use

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2642994

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 12280534

Country of ref document: US

Ref document number: 2007221255

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007751371

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2007221255

Country of ref document: AU

Date of ref document: 20070221

Kind code of ref document: A